Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1532-1539

  Schena, Elisa ^a   Nedialkova, Lubov ^b   Borroni, Emanuele ^a   Battaglia, Simone ^a   Cabibbe, Andrea Maurizio ^a   Niemann, Stefan ^c   Utpatel, Christian ^c   Merker, Matthias ^c   Trovato, Alberto ^a   Hofmann Thiel, Sabine ^b,d   Hoffmann, Harald ^b,d   Cirillo, Daniela Maria ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; RESAZURIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZINE DERIVATIVE; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; DDN GENE; DNA ISOLATION; FBIA GENE; FBIB GENE; FBIC GENE; FGD1 GENE; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; GENOME ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RESAZURIN MICROTITRE ASSAY; STOP CODON; SUPERNATANT; BACTERIAL GENE; COLORIMETRY; DNA SEQUENCE; DRUG EFFECTS; EVALUATION STUDY; LABORATORY AUTOMATION; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTITUBERCULAR AGENTS; AUTOMATION, LABORATORY; COLORIMETRY; GENES, BACTERIAL; INDICATORS AND REAGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZINES; OXAZOLES; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; XANTHENES;

EID: 84973370236     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw044     Document Type: Article

References (32)

1. WHO. Global Tuberculosis Report 2015. http://www.who.int/tb/publications/global_report/en/.
2. Ryan NJ, Lo JH. Delamanid: first global approval. Drugs 2014; 74: 1041-5.
3. Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015; 75: 91-100.
4. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid formultidrugresistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
5. Wells CD, Gupta R, Hittel N et al. Long-term mortality assessment of multidrug-resistant tuberculosis (MDR-TB) patients treated with delamanid. Eur Resp J 2015; 45: 1-3.
6. WHO. The Use of Delamanid in the Treatment of Multidrug-resistant Tuberculosis. 2014. http://www.who.int/tb/publications/delamanid-in-mdrtb-treatment/en/.
7. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
8. Skripconoka V, Danilovits M, Pehme L et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-400.
9. EMA, Committee for Medicinal Products for Human Use. Assessment Report Deltyba. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002552/human_med_001699.jsp& mid=WC0b01ac058001d124.
10. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-54.
11. Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
12. Palomino JC, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Anticrob Agents Chemother 2002; 46: 2720-2.
13. van Soolingen D, Hermans PW, De Haas PE et al. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29: 2578-86.
14. Feuerriegel S, Schleusener V, Beckert P et al. PhyResSE: aweb tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 2015; 53: 1908-14.
15. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 2013; 8: 579-85.
16. Grosset JH, Singer TG, Bishai WR. Newdrugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis. 2012; 16: 1005-14.
17. WHO. Policy Statement: Use of Liquid TB Culture and Drug Susceptibility Testing (DST) in Low and Middle Income Settings. Summary of the Expert Group Meeting on the Use of Liquid Culture Media. 2007. http://www.stoptb.org/wg/gli/assets/documents/EGM report_Use of Liquid Culture Media.pdf.
18. Bemer P, Palicova F, Rüsch-Gerdes S et al. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-4.
19. Campanerut PA, Ghiraldi LD, Spositto FL et al. Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. J Antimicrob Chemother 2011; 66: 1044-6.
20. Leclercq R, Cantón R, Brown DFJ et al. EUCASTexpert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013; 19: 141-60.
21. EUCAST. Setting Breakpoints for New Antimicrobial Agents, EUCAST SOP 1.1. 2013. www.eucast.org.
22. Keller PM, Hömke R, Ritter C et al. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother 2015; 59: 4352-5.
23. Hoffmann H, Kohl TA, Hofmann-Thiel S et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am J Respir Crit Care Med 2016; 193: 337-40.
24. Niehaus AJ, Mlisana K, Gandhi NR et al. High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. PLoS One 2015; 10: e0135003.
25. Zhang Z, Liu M, Wang Y et al. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis 2014; 33: 1959-66.
26. Malik S, Willby M, Sikes D et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: e39754.
27. Van Deun A, Barrera L, Bastian I et al. Mycobacterium tuberculosis strains with highly discordant rifampicin susceptibility test results. J Clin Microbiol 2009; 47: 3501-6.
28. Van Deun A, Aung KJ, Hossain A et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015; 19: 185-90.
29. Bashiri G, Rehan AM, Greenwood DR et al. Metabolic engineering of cofactor f420 production inMycobacteriumsmegmatis. PLoSOne 2010; 5: e15803.
30. Hartkoom RC, Ryabova OB, Chiarelli LR et al. Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2944-7.
31. Feuerriegel S, Köser CU, Baù D et al. Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011; 55: 5718-22.
32. Homolka S, Projahn M, Feuerriegel S et al. High resolution discrimination of clinical Mycobacterium tuberculosis complex strains based on single nucleotide polymorphisms. PLoS One 2012; 7: e39855.